Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT04614103
Trial Phases:	Phase II	Protocol IDs:	IOV-LUN-202 (primary) NCI-2020-11568 2020-003629-45 2024-510778-26-00
Eligibility:	18 - 70 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Iovance Biotherapeutics, Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04614103

Summary

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2
study evaluating LN-145 in patients with metastatic non-small-cell lung cancer

Objectives

LN-145 is a ready-to-infuse TIL therapy that utilizes an autologous TIL manufacturing
process, as originally developed by the NCI and further optimized by Iovance for the
treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study
involves patients receiving a non-myeloablative (NMA) lymphodepleting preparative
regimen, followed by infusion of autologous TIL, then finally followed by the
administration of IL-2.

Treatment Sites in Georgia

Georgia Cancer Center at Augusta University
1411 Laney Walker Boulevard
Augusta, GA 30912
www.augusta.edu/cancer/

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.